Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05255276 · ClinicalTrials.gov registry record · Phase 1
PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor.
A Phase 1 study, sponsored by Mirati Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT05255276 is a Phase 1 study that has completed, run by Mirati Therapeutics. The registered enrollment target is 36 participants.
The verdict
NCT05255276, a Phase 1 study, has completed, sponsored by Mirati Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
A Phase 1 Open-label, Two-cohort, One-sequence Crossover Study to Investigate the Effect of P glycoprotein Inhibitor (Itraconazole) and Inducer (Rifampin) on the Pharmacokinetics, Safety, and Tolerability of Sitravatinib in Healthy Subjects.
Interventions
- DRUG Rifampin
- DRUG Itraconazole
- DRUG Sitravatinib 50 mg
- DRUG Sitravatinib 100 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2022-02-02 |
| Est. Completion | 2023-02-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05255276
The ClinicalTrials.gov registry entry for NCT05255276 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mirati Therapeutics, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Rifampin is the first listed.
NCT05255276 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05255276 about?
NCT05255276 is a clinical study titled "PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor.". A Phase 1 Open-label, Two-cohort, One-sequence Crossover Study to Investigate the Effect of P glycoprotein Inhibitor (Itraconazole) and Inducer (Rifampin) on the Pharmacokinetics, Safety, and Tolerability of Sitravatinib in Healthy Subjects.
What is the current status of trial NCT05255276?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2022-02-02. Estimated completion is 2023-02-10.
What interventions are being tested in trial NCT05255276?
The interventions under investigation include: Rifampin (DRUG), Itraconazole (DRUG), Sitravatinib 50 mg (DRUG), Sitravatinib 100 mg (DRUG).
Who is sponsoring clinical trial NCT05255276?
This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.